Lymphoma

Research Article

FoxP3-Positive T-Regulatory Cells in Lymph Nodes with Mycosis Fungoides and Sézary Syndrome

Table 5

Clinical features and pertinent laboratory findings in the study patients.


Pt	Sex	Age, years	ClinDx		LN size (cm)	PathDx	LN grade	MG^#	% CD3	% CD4/CD8 (ratio)	% CD7	CD4/CD7	FoxP3 (cells/mm³)

1	M	86	MF-PT	T2N3M0B1b	3	CTCL^‡	4	Neg	90	93/2 (46.5)	37	2.4	32
2	F	64	MF-PT	T1N1aM0B0a	3	DL	1	Neg	94	81/12 (6.8)	82	1.1	68
3	M	68	MF-PT	T2N1aM0B0x	4	DL	0	Neg	77	71/8 (8.9)	50	1.5	90
4	M	70	MF-PT	T2N1aM0B0a	3	DL	2	Neg	77	62/14 (4.4)	65	1.2	172
5	F	67	MF-PQ	T2N1aM0B0x	2.5	DL	1	Neg	73	66/4 (16.5)	42	1.7	130
6	M	35	MF-PQ	T2N1aM0B0x	2	DL	1	Neg	55	26/11 (2.4)	45	1.2	85
7	F	74	MF-PQ	T2N1aM0B1a	3	DL	2	Neg	74	69/2 (34.5)	28	2.6	171
8	F	71	MF-PQ	T2N0M0B0x	1	DL	1	Neg	70	44/6 (7.3)	66	1.1	257
9	M	63	MF-T	T3N1xM0B0x	2	DL	1	Neg	58	53/10 (5.3)	50	1.2	82
10	F	35	MF-T	T3N1aM0B0a	4	DL	1	Neg	—	—	—	—	64
11	F	74	MF-T	T3N3M0B2	3	CTCL^‡	4	Pos	48	66/5 (13.2)	—	—	23
12	M	57	MF-T	T3N1bM0B1b	3	DL	1	Pos	46	21/7 (3.0)	49	0.9	98
13	F	68	MF-T	T3N3M0B1x	4	CTCL	4	Pos	81	61/23 (2.7)	31	2.6	37
14	M	67	MF-E	T4N1aM0B0a	3	DL	2	Neg	85	71/16 (4.4)	73	1.2	223
15	M	45	NOS	T4N1aM0B0a	2	DL	1	Neg	—	—	—	—	147
16	F	83	NOS	T4N1bM0B1b	2	DL	1	Pos	48	43/5 (8.6)	40	1.2	99
17	M	61	NOS	T4N1aM0B0a	3	DL	2	Neg	63	55/7 (7.9)	54	1.2	123
18	F	48	NOS	T4N1aM0B0a	2	DL	1	Neg	56	37/12 (3.1)	28	2.0	96
19	F	73	NOS	T4N3M0B0a	2	CTCL	4	Pos	54	44/9 (4.9)	48	1.1	7
20	F	30	SS	T4N3M0B2	4	CTCL	4	Pos	24	15/4 (3.7)	14	1.7	63
21	M	59	SS	T4N3M0B2x	5	CTCL^‡	4	Pos	59	56/8 (7.0)	22	2.7	17
22	M	71	SS	T4N3M0B2	3.5	CTCL	4	Pos	90	88/10 (8.8)	10	9.0	0
23	M	80	SS	T4N3M0B2	3	CTCL	4	Neg	67	88/2 (42.0)	59	1.1	10
24	M	74	SS	T4N3M1B2	7	CTCL^‡	4	Pos	96	98/2 (49.0)	72	1.3	189
25	F	69	SS	T4N3M0B2	3	CTCL	4	Pos	51	65/12 (5.4)	11	4.6	58
26	F	84	SS	T4N3M0B2	2	CTCL	4	Pos	92	87/2 (43.5)	93	1.0	35

Status at time of lymph node biopsy.
TNMB ratings according to Olsen et al. [3]. Lower case “x” signifies missing molecular analysis for T-cell clonality.
^†Maximum lymph node size based on clinical assessment or CT scan (not necessarily biopsied).
^‡Evidence of large-cell transformation.
Lymph node grading according to NCI-MFCG criteria [23]. LN0-2 and LN4 used to define DL and CTCL, respectively.
^#All specimens studied for T cell receptor gamma gene rearrangment by polymerase chain reaction followed by denaturing gradient electrophoresis except for patients 2 and 19 (PCR-single strand conformational electrophoresis), patients 9, 10 and 21 (PCR-fluorophore labeled primer with capillary gel electrophoresis) and patient 22 (Southern blot technique).
Abbreviations: Pt: patient number; ClinDx: clinical assessment; TNMB: tumor-node-metastasis-blood; LN: lymph node; MG: T cell clonality by molecular testing; CTCL: cutaneous T cell lymphoma; MF: mycosis fungoides, patch (PT), plaque (PQ), tumor (T) phases; MF-E: erythroderma preceded by MF; NOS: not otherwise specified; SS: Sézary syndrome; PathDx: histological assessment; DL: dermatopathic lymphadenitis.